Project Grant HT94252510582
Award Date 9/15/25
Completion Date 9/14/28
Dollars Obligated $1.1M
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Philadelphia, PA 19104, USA
Similar Awards
- The federal Project Grant award of $442,557.00 was provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to The Wistar Institute of Anatomy and Biology located in Philadelphia, PA. The funding supports advanced biomedical research aimed at developing immunotherapeutic approaches targeting SLC39A9 in CDKN2A-low melanoma. The Wistar Institute, an independent non-profit research institute, has demonstrated extensive capabilities in cancer...
- The Department of Defense's Defense Health Agency awarded a $1,194,425 Project Grant to The Wistar Institute of Anatomy and Biology to support a 3-year research project titled "DEVELOPING RATIONAL APPROACHES FOR ACRAL MELANOMA" under the Military Medical Research and Development program (CFDA 12.420). The grant will fund basic, translational, and clinical research aimed at developing new treatments and advancing scientific understanding of acral melanoma, a rare form of skin cancer. As...
- The Department of Defense's Defense Health Agency awarded a $1,821,000 Project Grant under the Military Medical Research and Development program (CFDA 12.420) to The Wistar Institute of Anatomy and Biology, an independent biomedical research institute in Philadelphia. The grant, awarded on May 15, 2024, supports research into the "Immunomodulatory Role of Acetate Metabolism in Breast Cancer" over a 3-year performance period ending on May 14, 2027. As a recognized leader in cancer,...
- The U.S. Defense Health Agency awarded a $999,006 Project Grant to The Wistar Institute of Anatomy and Biology in Philadelphia, PA under the Military Medical Research and Development program (CFDA 12.420). The grant, effective September 30, 2023 through September 29, 2026, will fund research on Epstein-Barr virus-driven B-cell inflammation and central nervous system trafficking in multiple sclerosis. The Wistar Institute has previously served as a subcontractor on federal grants, providing...
- The University of Pittsburgh has been awarded a $726,989 Project Grant from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) to conduct research on "IMMUNOTHERAPEUTIC TARGETING OF SLC39A9 IN CDKN2A-LOW MELANOMA." The three-year award, commencing on September 15, 2025, aims to advance biomedical research to transform healthcare for military service members, veterans, and the broader public. The research project will investigate medical...
- This Project Grant award, titled "OVERCOMING IMMUNOTHERAPY RESISTANCE IN ACRAL MELANOMA", is provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). The $1,183,560 award to the University of Pittsburgh will support advanced biomedical research aimed at transforming healthcare for military service members, veterans, and the broader public. The research project, running from September 1, 2025 to August 31, 2028, will focus on...
- The Department of Defense's Defense Health Agency awarded a $558,832 Project Grant to Tufts University School of Medicine under the Military Medical Research and Development program (CFDA 12.420) on September 30, 2024. This grant will support research focused on "Targeting Differentiation Epitope in CD11b of Tumor-Associated Inflammatory Monocytes: A Novel Adjuvant Dendritic Cell Therapy Approach for Mucosal Melanoma." The research aims to develop an innovative dendritic cell-based...
- The University of Pittsburgh was awarded a $1,144,800 Project Grant by the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) to conduct research on "Overcoming Immunotherapy Resistance in Acral Melanoma." The three-year project, starting on September 1, 2025, and completing on August 31, 2028, aims to investigate innovative medical solutions to address this critical health challenge relevant to military personnel and the broader...
- The Institute For Cancer Research has been awarded a $940,000 Project Grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to conduct a mouse model study of epigenetic events in melanomagenesis. This 3-year grant, with a period of performance from July 1, 2024 to June 30, 2027, will enable the non-profit research organization to investigate the underlying epigenetic mechanisms driving the development of melanoma. As a prime grantee, The...
- The Defense Health Agency has awarded a $657,263 project grant under the Military Medical Research and Development program (CFDA 12.420) to the Dana-Farber Cancer Institute, Inc. (d.b.a. DFCI) in Boston, MA. The award, effective September 1, 2024 through August 31, 2027, will support DATA-DRIVEN BIOMARKER-INFORMED DECISION ANALYTICS IN MELANOMA: IMPROVING EFFICACY AND REDUCING TOXICITY OF IMMUNE CHECKPOINT BLOCKADE. Through this grant, DFCI will conduct research to develop data-driven...